Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two pharmaceutical drugs, carbamazepine and citalopram. Carbamazepine is an anticonvulsant and analgesic primarily used to treat seizure disorders (such as epilepsy), trigeminal neuralgia (a type of nerve pain), and bipolar disorder. It acts mainly by inhibiting voltage-gated sodium channels in the brain, stabilizing hyperexcited nerve membranes, inhibiting repetitive neuronal firing, and reducing synaptic propagation of excitatory impulses[3][4]. Citalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant used to treat major depressive disorder. It works by increasing serotonin levels in the brain through inhibition of its reuptake into presynaptic cells[7][8]. When combined, these drugs may interact pharmacokinetically; carbamazepine induces hepatic enzymes (notably CYP3A4), which can lower plasma concentrations of citalopram and potentially reduce its efficacy[5][6][8]. This combination should be monitored closely due to possible reduced antidepressant effect and increased risk for side effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carbamazepine + citalopram.